GSTM1 and Neurodevelopmental delay: Clinical trials have found that daprodustat appeared to be well tolerated and to increase EPO levels in a dose-dependent manner [77]; treatment also appeared to increase Hb levels compared with placebo in NDD-CKD [78], maintain stable Hb levels after conversion from ESAs to daprodustat, and lower SF levels [79].